NO312679B1 - N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat - Google Patents

N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat Download PDF

Info

Publication number
NO312679B1
NO312679B1 NO19990787A NO990787A NO312679B1 NO 312679 B1 NO312679 B1 NO 312679B1 NO 19990787 A NO19990787 A NO 19990787A NO 990787 A NO990787 A NO 990787A NO 312679 B1 NO312679 B1 NO 312679B1
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical composition
compound
same
receptor
Prior art date
Application number
NO19990787A
Other languages
English (en)
Norwegian (no)
Other versions
NO990787D0 (no
NO990787L (no
Inventor
Robert T Lum
Jurg Roland Pfister
Steven R Schow
Michael M Wick
Marek G Nelson
George F Schreiner
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO990787D0 publication Critical patent/NO990787D0/no
Publication of NO990787L publication Critical patent/NO990787L/no
Priority to NO20020759A priority Critical patent/NO20020759D0/no
Priority to NO20020758A priority patent/NO322459B1/no
Publication of NO312679B1 publication Critical patent/NO312679B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19990787A 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat NO312679B1 (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08702234 US5789416B1 (en) 1996-08-27 1996-08-27 N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives

Publications (3)

Publication Number Publication Date
NO990787D0 NO990787D0 (no) 1999-02-19
NO990787L NO990787L (no) 1999-02-19
NO312679B1 true NO312679B1 (no) 2002-06-17

Family

ID=24820367

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19990787A NO312679B1 (no) 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Country Status (24)

Country Link
US (1) US5789416B1 (de)
EP (3) EP0920438B1 (de)
JP (1) JP3157842B2 (de)
KR (1) KR100331775B1 (de)
CN (1) CN100363377C (de)
AT (2) ATE234323T1 (de)
AU (1) AU726597B2 (de)
BR (1) BR9711444A (de)
CA (1) CA2264155C (de)
CZ (1) CZ296855B6 (de)
DE (2) DE69719816T2 (de)
DK (2) DK0992510T3 (de)
ES (2) ES2189330T3 (de)
GE (1) GEP20012419B (de)
GR (1) GR3036332T3 (de)
HU (1) HU226057B1 (de)
IL (2) IL128652A0 (de)
NO (3) NO312679B1 (de)
NZ (3) NZ505428A (de)
PL (1) PL187635B1 (de)
PT (1) PT920438E (de)
TR (2) TR199900377T2 (de)
UA (1) UA62936C2 (de)
WO (1) WO1998008855A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
CN1370170A (zh) * 1999-05-25 2002-09-18 宾夕法尼亚州研究基金会 Dna甲基转移酶抑制剂
EP1420021A1 (de) * 1999-05-25 2004-05-19 The Penn State Research Foundation DNA Methyltransferas-Inhibitoren
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
MXPA03001741A (es) * 2000-09-08 2004-09-10 Cv Therapeutics Inc Ribosidos de purina como antiarritmicos.
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
AU2003205089B2 (en) * 2002-01-10 2007-01-25 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
CA2476683C (en) 2002-02-19 2011-11-01 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
WO2003097643A1 (en) 2002-05-17 2003-11-27 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
NZ541651A (en) * 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
MXPA05011428A (es) * 2003-04-24 2006-05-31 Aderis Pharmaceuticals Inc Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) * 2004-04-21 2005-04-19 Eastman Chemical Company Preparation of tetrahydro-3-furoic acid
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
BRPI0515506A (pt) * 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso dos mesmos
CN100451010C (zh) * 2004-12-21 2009-01-14 厦门大学 一种合成(r)-3-氨基四氢呋喃的方法
JP5042996B2 (ja) * 2005-05-19 2012-10-03 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
CN100344768C (zh) * 2005-11-24 2007-10-24 东华大学 一种3－(s)－氨基四氢呋喃的酶法合成方法
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
EP2247729B1 (de) 2008-02-11 2019-05-01 Phio Pharmaceuticals Corp. Modifizierte rnai-polynukleotide und verwendungen davon
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2340309A2 (de) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutrale nanotransporter
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
CA2932753A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
CN105218490B (zh) * 2015-11-10 2017-05-03 山东川成医药股份有限公司 一种（r）‑3‑氨基四氢呋喃的制备方法
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
CA3160657A1 (en) 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021138537A1 (en) 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
WO2023015265A2 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
CA1255297A (en) * 1984-10-26 1989-06-06 Bharat Trivedi N.sup.6-benzopyrano and benzothiopyrano adenosines
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
WO1990009178A1 (en) * 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
EP0704215A3 (de) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Hemmer der Erhöhung vaskulärer Permeabilität

Also Published As

Publication number Publication date
TR199900377T2 (xx) 1999-05-21
HUP0001640A2 (hu) 2001-05-28
HK1020967A1 (en) 2000-05-26
HUP0001640A3 (en) 2002-04-29
WO1998008855A3 (en) 1998-09-03
EP0920438B1 (de) 2001-06-20
PL331853A1 (en) 1999-08-16
EP1081155A2 (de) 2001-03-07
KR100331775B1 (ko) 2002-04-09
KR20000035867A (ko) 2000-06-26
JP3157842B2 (ja) 2001-04-16
NZ334095A (en) 2000-10-27
NO322459B1 (no) 2006-10-09
PT920438E (pt) 2001-10-30
AU4080997A (en) 1998-03-19
ATE234323T1 (de) 2003-03-15
CZ61499A3 (cs) 1999-10-13
DE69705312D1 (de) 2001-07-26
JP2000501426A (ja) 2000-02-08
DK0920438T3 (da) 2001-09-10
US5789416B1 (en) 1999-10-05
NO990787D0 (no) 1999-02-19
EP0920438A2 (de) 1999-06-09
IL128652A (en) 2008-06-05
TR200202287T2 (tr) 2003-01-21
NO20020759D0 (no) 2002-02-15
UA62936C2 (en) 2004-01-15
CN100363377C (zh) 2008-01-23
NO20020758L (no) 1999-02-19
EP0992510B1 (de) 2003-03-12
DE69705312T2 (de) 2001-10-11
NO20020758D0 (no) 2002-02-15
CA2264155C (en) 2003-11-18
CA2264155A1 (en) 1998-03-05
HU226057B1 (en) 2008-04-28
GR3036332T3 (en) 2001-11-30
NZ512242A (en) 2004-01-30
DE69719816D1 (de) 2003-04-17
ES2157593T3 (es) 2001-08-16
IL128652A0 (en) 2000-01-31
NO990787L (no) 1999-02-19
ATE202361T1 (de) 2001-07-15
WO1998008855A2 (en) 1998-03-05
ES2189330T3 (es) 2003-07-01
CZ296855B6 (cs) 2006-07-12
NZ505428A (en) 2005-03-24
US5789416A (en) 1998-08-04
GEP20012419B (en) 2001-04-25
BR9711444A (pt) 2000-01-18
NO20020759L (no) 1999-02-19
DK0992510T3 (da) 2003-07-07
PL187635B1 (pl) 2004-08-31
EP1081155A3 (de) 2003-05-02
AU726597B2 (en) 2000-11-16
CN1234803A (zh) 1999-11-10
DE69719816T2 (de) 2003-12-18
EP0992510A1 (de) 2000-04-12

Similar Documents

Publication Publication Date Title
NO322459B1 (no) N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
US6770634B1 (en) C-pyrazole a2a receptor agonists
NO323138B1 (no) N&lt;O&gt;6&lt;/O&gt;-heterosykliske, 8-modifiserte adenosinderivater og farmasoytiske sammensetninger omfattende samme.
MXPA04008008A (es) Agonistas parciales y completos de receptores de adenosina a1.
JPH0613506B2 (ja) 抗不整脈剤
JP4596913B2 (ja) Ａ１アデノシン受容体の部分および完全アゴニスト
JPH07502273A (ja) ベンゾピラン　クラス３抗不整脈薬
US4882323A (en) 1,2,3,4,5,6-hexahydro[1,3,6]triazocino[1,1-a]benzimidazoles
PT89422A (pt) Processo para a preparacao de 2,5-diazabiciclo{2.2.1}heptanos uteis como agentes anti-arritmicos
US4935515A (en) 2,3,4,5-tetrahydro-1H-[1,2,5]triazocino(1,2-a)[1,2,4]benzotriazin-7(8H)-ones, thiones and derivatives
MXPA99001509A (en) N6
HK1020967B (en) N6 heterocyclic substituted adenosine derivatives

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees